发明授权
- 专利标题: Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
- 专利标题(中): 抗增殖和抗炎剂组合用于用植入式医疗装置治疗血管疾病
-
申请号: US12191209申请日: 2008-08-13
-
公开(公告)号: US08435550B2公开(公告)日: 2013-05-07
- 发明人: Jin Cheng , Stephen Dugan , Gordon Stewart , Gina Zhang , Nancy Kirsten , Paul Consigny , Christopher Feezor , Gene Park , Wouter Roorda , Syed F. A. Hossainy
- 申请人: Jin Cheng , Stephen Dugan , Gordon Stewart , Gina Zhang , Nancy Kirsten , Paul Consigny , Christopher Feezor , Gene Park , Wouter Roorda , Syed F. A. Hossainy
- 申请人地址: US CA Santa Clara
- 专利权人: Abbot Cardiovascular Systems Inc.
- 当前专利权人: Abbot Cardiovascular Systems Inc.
- 当前专利权人地址: US CA Santa Clara
- 代理机构: Squire Sanders (US) LLP
- 主分类号: A61F2/02
- IPC分类号: A61F2/02
摘要:
A drug-delivery system is provided including at least 100 μg of everolimus and clobetasol, such that the ratio of everolimus to clobetasol is at least 10:1 (w/w) or the amount of everolimus by weight is at least 10 times more than clobetasol. The system can be a stent. Also provided a method of treating restenosis or vulnerable plaque of a blood vessel, the method includes locally administering to a patient a first drug selected from a group consisting of rapamycin (sirolimus), Biolimus A9, deforolimus, AP23572, tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40-O-(2-hydroxy)ethylrapamycin (everolimus), 40-O-(3-hydroxy)propylrapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethylrapamycin, 40-O-tetrazolylrapamycin and 40-epi-(N1-tetrazolyl)rapamycin, and locally administering to a patient a second drug consisting of clobetasol, wherein the minimum amount of the first drug that is locally administered is 100 μg, and wherein the ratio of the first drug to the second drug is, for example, 10:1 to 100:1 (w/w).